All In Biotech

Drug Trial Radar · NCT05399069

Safety and Tolerability of VGR-R01 in Patients With Bietti Crystalline Dystrophy

An Open-Label Safety Study of Single-dose VGR-R01 in Patients With Bietti Crystalline Dystrophy

Last checked: Nov 19, 2026Latest source record: Nov 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

3

Planned (sponsor's estimate)

Start

Sep 15, 2022

Primary completion

May 2024

Study completion May 2024

Sponsor

Lead sponsor
Beijing Tongren HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An Open-Label, Non-Randomized, Uncontrolled, Single-dose Pilot Study of VGR-R01 in Patients with Bietti Crystalline Dystrophy.

Conditions

  • Bietti Crystalline Dystrophy

Interventions

  • VGR-R01Drug

    Gene Replacement Therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventsTime frame: Baseline up to Day 365
  2. Incidence of serious adverse eventsTime frame: Baseline up to Day 365
  3. Number of Participants with Clinically Significant Change from Baseline in Vital SignsTime frame: Baseline up to Day 365
  4. Number of Participants with Clinically Laboratory AbnormalitiesTime frame: Baseline up to Day 365
  5. Number of Participants with Clinically Significant Change from Baseline in Ophthalmic Examination FindingsTime frame: Baseline up to Day 365

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tongren Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.